Live
- NTR Vaidya Seva services in Ramesh Hospitals soon
- Industrial pollution taking toll on lives of city dwellers
- Anantapur should be made second capital, demands Nagaraju
- High-speed internet connectivity to every school: Collector Basha
- Sai Trust sponsors skill training to 100 youth
- All India Craft Mela 2024 begins at Shilparamam
- Tributes paid to ‘Amarajeevi’ on death anniv
- Fresh batch of EMBA commences at IIM-V
- YSRCP leaders demand apology from CI
- Only free universal education from KG to PG can make healthy, vibrant democracy
Hyderabad: Anti-diabetic drug shows promise in curing Covid-19
Anti-diabetic drug shows promise in curing Covid-19
ReaGene Innovations Private Limited, a startup company incubated at the ASPIRE-BioNEST, and INDRAS Private Limited have a rationale for an anti-diabetic drug Ertugliflozin, as repurposed drug from the in-vitro and in-silico studies, respectively, might provide a therapeutic solution to the Covid-19 infection
Hyderabad: ReaGene Innovations Private Limited, a startup company incubated at the ASPIRE-BioNEST, and INDRAS Private Limited have a rationale for an anti-diabetic drug Ertugliflozin, as repurposed drug from the in-vitro and in-silico studies, respectively, might provide a therapeutic solution to the Covid-19 infection.
Their findings indicate that this repurposed drug not only binds effectively to the receptor binding domain of the spike protein of Covid-19 further blocks binding to human ACE2 but also displays significant anti-inflammatory and antithrombotic properties in a 3D human vascular lung model, both of which are fundamentals in covid-19 infection.
This is the first result that offers a safe, ready-to-use, cost-effective solution to humans who contract Covid-19. "It has immense potential to treat Covid-19 infection, and our research proves its efficacy in the test-tube assays", says Dr. Uday Saxena, CEO of ReaGene Innovations, co-founded with Dr. Subramanyam Vangala, and Dr Sreedhara Voleti, MD of INDRAS. Ertugliflozin is an FDA approved drug for type-2 diabetes, works as SGLT-2 inhibitor by removing excessive glucose through urine.
INDRAS focus is on consulting, contracting, and collaborative solutions to in-silico drug design, has prioritized about 8000 FDA approved drugs to top-10 from their computational studies, which were further experimented by ReaGene Innovations for various in-vitro assays on cytokine storm, antithrombotic properties, and inflammatory marker reduction through various in vitro assays.
The path to find such a repurposed drug was critically planned and completed within a year of funding from the IT giant, Tech Mahindra. "We have found a molecule that can potentially attack corona virus. We have applied for a joint patent," said Nikhil Malhotra, Global head of Makers Lab. The obtained results are highly encouraging, and further in animal models towards preclinical and clinical outcomes in humans are yet to be conducted for this drug to be officially nominated as a therapeutic agent for Covid-19.
